Families pay thousands for an unproven autism treatment. Researchers say we need ethical guidelines for marketing the tech

Wave Neuroscience's Magnetic E-Resonance Therapy (MERT), an off-label application of transcranial magnetic stimulation, is being marketed for autism at costs exceeding $10,000 per course despite lacking FDA approval and significant scientific evidence of efficacy. Researchers are calling for ethical guidelines on such marketing, citing MERT as a prime example where promotional claims of "miraculous results" are not supported by data, raising concerns about vulnerable families paying for unproven treatments and highlighting potential regulatory scrutiny for companies operating in this space.

Analysis

Wave Neuroscience's Magnetic E-Resonance Therapy (MERT) is marketed for autism at over $10,000 per course, despite lacking specific FDA approval for this indication. While based on FDA-approved transcranial magnetic stimulation (TMS) for other conditions, MERT has not undergone clinical trials for autism, raising significant efficacy and ethical concerns.

Prominent researchers, including Dr. Andrew Leuchter, criticize MERT as an example of off-label TMS with "negligible evidence of efficacy" for core autism symptoms. An editorial highlights the "extremely limited scientific evidence" for any TMS form in improving ASD symptoms, cautioning against promotional materials that create false expectations through testimonials.

The absence of robust scientific data and reliance on anecdotal evidence exposes Wave Neuroscience and associated clinics to heightened regulatory scrutiny. Calls for ethical guidelines by leading experts suggest a potential shift towards stricter oversight for unproven treatments targeting vulnerable populations. This implies considerable reputational and operational risks for companies in this segment.

Key Decisions for Investors

• Monitor regulatory developments closely for off-label medical device applications, particularly in vulnerable patient populations, as increased scrutiny is likely.
• Scrutinize the R&D pipelines and clinical trial progress of companies in the neurostimulation and autism treatment space, prioritizing those with robust, evidence-based development.
• Evaluate the reputational and legal risks associated with companies marketing high-cost, unproven therapies, as these can significantly impact long-term valuation and operational stability.